JESSICA CHU: Open Payments
NPI 1063076586 · NEW ORLEANS, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,232 in 61 payments from 18 companies in 2025. Trend: 2023 $257 · 2024 $2,049 · 2025 $1,232
Food & beverage: $1,232
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 17 | $310 |
| Dexcom, Inc. | 6 | $228 |
| Xeris Pharmaceuticals, Inc. | 5 | $108 |
| Lilly USA, LLC | 7 | $104 |
| Amgen Inc. | 4 | $89 |
| BETA BIONICS, INC. | 6 | $88 |
| Corcept Therapeutics | 2 | $45 |
| SANOFI-AVENTIS U.S. LLC | 2 | $44 |
| Medtronic, Inc. | 3 | $43 |
| RECORDATI_RARE_DISEASES_INC. | 1 | $23 |
Products named: Ozempic, Dexcom G6 Transmitter, MOUNJARO, iLet Bionic Pancreas, GVOKE HYPOPEN, TEPEZZA, Korlym, TZIELD.
Industry payments across LA — which companies pay providers there.
